

NUZYRA[®] may provide patients the ability to receive antibiotic therapy in a lower risk setting

ai anti-infectives

Option Care Health[®] is proud to be a limited pharmacy network provider of NUZYRA, a once-daily intravenous (IV) and oral antibiotic

- Approved treatment for patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections¹
- Available as a monotherapy in IV and oral formulations¹
- Activity against select gram-positives, gram-negatives and atypicals, including drug-resistant strains such as MRSA¹
- No dosage adjustment required for renal or hepatic impairment¹
- May be used as an alternative for patients with fluoroquinolone, beta-lactam or sulfa allergies¹


NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs or to any of the excipients.

Prescribe once-daily NUZYRA - a modernized tetracycline for tough-to-treat pathogens, including MRSA.¹

IV
Formulation



OR



Oral
Formulation

To refer your NUZYRA patients, call **866.827.8203** or visit [optioncarehealth.com](https://www.optioncarehealth.com)

Please see Indications and Usage for NUZYRA on the back.



Indications and Usage

1.1 Community-Acquired Bacterial Pneumonia (CABP)

NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*.

1.2 Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NUZYRA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus* grp. (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, and *Klebsiella pneumoniae*.

1.3 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.